

# Novel pyrrole C-nucleosides by nitrogen extrusion from pyridazine C-nucleosides

Uday Joshi,<sup>a</sup> Solen Josse,<sup>a</sup> Muriel Pipelier,<sup>a</sup> Floris Chevallier,<sup>a</sup> Jean-Paul Pradère,<sup>a</sup> Roland Hazard,<sup>b</sup> Stéphanie Legoupy,<sup>c</sup> François Huet<sup>c</sup> and Didier Dubreuil<sup>a,\*</sup>

<sup>a</sup>Laboratoire de Synthèse Organique (UMR 6513), University of Nantes, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex, France

<sup>b</sup>Laboratoire d'Electrochimie, URA CNRS no. 439, Campus de Beaulieu, 35042 Rennes Cedex, France

<sup>c</sup>Laboratoire de Synthèse Organique (UMR 6011), Université du Maine, av. Olivier Messiaen, 72085 Le Mans Cedex 9, France

Received 30 September 2003; revised 13 November 2003; accepted 19 November 2003

**Abstract**—Pyridazine C-nucleosides have been synthesized by [4+2] cycloaddition of alkynyl C-nucleosides with substituted tetrazines. These pyridazines on extrusion of a nitrogen atom afforded novel pyrrole C-nucleosides with good yields. The results of electrochemical and chemical reduction are compared.

© 2003 Elsevier Ltd. All rights reserved.

## 1. Introduction

C-Nucleosides bearing five-membered nitrogen heterocycles such as thiazofurin, pyrazomycin, showdomycin etc. and their analogs are known to possess varied biological activities.<sup>1</sup> C-Nucleosides bearing a nitropyrrole are known for their biochemical and pharmacological activities.<sup>2</sup> Recently Burnham et al.<sup>3</sup> reported that pyrrole C-nucleosides also exhibit anticancer activity. Even simple substituted pyrroles are known to exhibit anti-neoplastic, antileukemic activities.<sup>4</sup>

This led us toward the synthesis of novel functionalized pyrrole C-nucleosides. In the last few years we have successfully developed an electrochemical method for the synthesis of substituted pyrroles from pyridazines.<sup>5</sup> In this process the latter undergo extrusion of a nitrogen atom to afford the corresponding substituted pyrrole derivatives by a controlled potential electroreduction.

This process appears complementary to that of Boger's strategy using Zn/AcOH to achieve the ring contraction of diazaheterocycles.<sup>6</sup>


It was thus obvious to attempt the same methodology toward the synthesis of pyrrole C-nucleosides in order to test their biological activity. Herein we wish to summarize our results on the electrochemical as well as the chemical transformation of pyridazine C-nucleosides to the corresponding pyrrole C-nucleosides.

## 2. Preparation of pyridazine C-nucleosides 4

In the first place the pyridazine C-nucleosides **4** were prepared by the procedure described by Seitz and co-worker.<sup>7</sup> D-(–)-Ribose (**1**) was converted to furanose **2** by a conventional method. Treatment of intermediate **2** with appropriate alkynyl Grignard's reagents, prepared in situ, and cyclization of the resulting open-chain compound through selective tosylation of the propargylic hydroxy group, afforded the corresponding alkynyl sugars **3a–b**, in 25% and 40% overall yields, respectively (Scheme 1). The β-isomer was found to be the major isomer in every case (β:α = 8:2). Having alkynyl sugars in hand, they were converted to pyridazine C-nucleosides **4a–b** by inverse demand hetero Diels–Alder reactions with dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate<sup>8</sup> as described by Seitz and co-worker.<sup>7</sup> By slight changes in the reaction conditions, we were successful in significantly increasing the yields of the individual steps for the synthesis of pyridazine C-nucleosides **4a–b**. Thus the

**Keywords:** Pyridazine C-nucleosides; Ring contraction; Pyrrole C-nucleosides.

\* Corresponding author. Tel.: +33-251125420; fax: +33-251125402; e-mail: [didier.dubreuil@chimie.univ-nantes.fr](mailto:didier.dubreuil@chimie.univ-nantes.fr)



**Scheme 1.** Reagents and conditions: (a) (i) MeOH, catalytic H<sub>2</sub>SO<sub>4</sub>, (ii) NaH, THF/DMF, BnBr, rt, (iii) AcOH, 1 M H<sub>2</sub>SO<sub>4</sub>, 100 °C; (b) (i) R–C≡C–MgBr, THF, 60 °C, (ii) TsCl, pyridine, 60 °C; (c) dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate, toluene, reflux.

yield of the [4+2] cycloaddition reaction was optimized to 56% in the case of **4a** and 65% in the case of **4b**, respectively.<sup>9</sup>

### 3. Nitrogen extrusion by the electrochemical method

The next step was to convert these pyridazine C-nucleosides **4a–b** into the corresponding pyrrole derivatives. In a typical electroreduction experiment, previously optimized in our laboratory,<sup>10</sup> the electrolysis of a solution of the pyridazine derivative in the electrolytic system, comprised of ethanol and acidic buffer, was carried out in the potential range of –0.8 to –1.2 E/(V vs SCE). The potential range was determined on the basis of the polarograms of the pyridazine derivatives, which indicated two successive bielectronic steps [ $E_{1/2} = -0.9$  and –1.1 E/(V vs SCE)]. Cyclic voltammetry was performed at a sweep rate of 0.2 V s<sup>-1</sup>. The polarogram and the cyclic voltamogram are shown in Figure 1. The mechanism of the electrochemical transformation of pyridazines to pyrrole rings, consisting of a stepwise transfer of four electrons and four protons, has already


**Table 1**

Entry	Pyridazine	R	Method	Yield of 5 (%)
1	<b>4a</b>	Ph	Electrolysis	74
2	<b>4b</b>	<i>n</i> -Bu	Electrolysis	18
3	<b>4a</b>	Ph	Zn, AcOH, rt, 24 h	63
4	<b>4b</b>	<i>n</i> -Bu	Zn, AcOH, rt, 24 h	34
5	<b>4b</b>	<i>n</i> -Bu	Zn, AcOH, 60 °C, 24 h	53
6	<b>4b</b>	<i>n</i> -Bu	Zn, AcOH, reflux, 15 h	63


been described and can be transposed to the pyridazine C-nucleoside precursors.<sup>10</sup> Thus in the case of **4a**, the yield of the reaction was very good (75%) but, surprisingly, in the case of **4b**, the corresponding pyrrole was isolated in only low yield (18%) along with the undesired side products. In the case of **4a**, no formation of side products was observed. The results are summarized in Table 1.

### 4. Nitrogen extrusion by chemical methods

The low yield obtained in the case of **4b** led us to carry out the same transformation by chemical means. Thus, treatment of **4a** with zinc and acetic acid at room temperature for 24 h followed by the work up procedure as described by Boger et al.,<sup>6</sup> and purification of the crude product by column chromatography on silica gel afforded the desired pyrrole derivative, as shown in Scheme 2. In this case, the yield was comparable (63%) to that of the electrochemical method, whereas in the case of **4b**, the desired pyrrole derivative was isolated in only 34% yield. However, improvement in the yield of **4b** was achieved (63%) when the reaction was carried out at a higher temperature. The results are summarized in Table 1.



**Figure 1.** Cyclic voltamogram (A) and polarogram (B) of pyridazine C-nucleosides.



**Scheme 2.** Reagents and conditions: (a) Zn, AcOH or electrolysis; (b) H<sub>2</sub>/Pd–C, ethyl acetate, rt.

In the last step, the benzyl protecting groups were removed by conventional hydrogenolysis of **5a–b**, as shown in Scheme 2, to afford the novel pyrrole C-nucleosides<sup>11</sup> (**6a–b**) in excellent yields (>85%).

In summary, we have synthesized novel pyrrole C-nucleosides by a nitrogen extrusion strategy. Some exploratory work such as the synthesis of pyridazine C-nucleosides with different substituents and their electrolysis under basic conditions is being undertaken in order to study the behavior of the pyridazine derivatives. The biological evaluation of novel pyrrole C-nucleosides for their anticancer activity, is currently in progress.

### Acknowledgements

This work was supported by the ‘Ministère de l’Éducation Nationale de la Recherche et de la Technologie’ with a doctoral fellowship to S.J. and a postdoctoral fellowship to U.J. We also thank CNRS and the ‘Conseil Régional des Pays de la Loire’.

### References and notes

- (a) Petrie, C. R.; Revankar, G. R.; Dalley, N. K.; George, R. D.; McKernan, P. A.; Hamill, R. L.; Robins, R. K. *J. Med. Chem.* **1986**, *29*, 268–278; (b) Hammerschmidt, F.; Peric, B.; Ohler, E. *Monatsh. Chem.* **1997**, *128*, 183–190; (c) Franchetti, P.; Marchetti, S.; Cappellacci, L.; Yalowitz, J. A.; Jayaram, H. N.; Goldstein, B. M.; Grifantini, M. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 67–69; (d) Hungerford, N. L.; Armit, D. J.; Banwell, M. G. *Synthesis* **2003**, 1837–1843.
- Fernandez-Bolanos, J.; Mota, J. F.; Ramirez, I. R. *An. Quim., Ser. C: Quim. Org. Bioquim.* **1984**, *80*, 123–126, and references cited therein.
- Lam, K. S.; Glersaye, S.; Patel, K.; Najmi, S.; Burnham, B. S. *Abstracts of Papers*, 225th ACS National Meeting, New Orleans, LA, United States, March 23–27, 2003.
- Anderson, W. K.; Heider, A. R. *J. Med. Chem.* **1986**, *29*, 2392–2395.
- Manh, G. T.; Hazard, R.; Pradère, J. P.; Tallec, A.; Raoult, E.; Dubreuil, D. *Tetrahedron Lett.* **2000**, *41*, 647–650.
- Boger, D. L.; Coleman, R. S.; Panek, J. S.; Yohannes, D. *J. Org. Chem.* **1984**, *49*, 4405–4409.
- Richter, M.; Seitz, G. *Arch. Pharm. (Weinheim)* **1994**, *327*, 365–370.
- Boger, D. L.; Coleman, R. S.; Panek, J. S.; Huber, F. X.; Sauer, J. *J. Org. Chem.* **1985**, *50*, 5377–5379.
- 45% for **4b** as reported by Seitz.<sup>6</sup> Even in the case of **4a** the yield was about 35% when Seitz’s conditions were followed.
- Manh, G. T.; Hazard, R.; Tallec, A.; Pradère, J. P.; Dubreuil, D.; Thiam, M.; Toupet, L. *Electrochim. Acta* **2002**, *47*, 2833–2841.
- 2,5-Bis(methoxycarbonyl)-4-phenyl-3-(β-D-ribofuranosyl)-1H-pyrrole **6a**: Mp 83–84 °C (as colorless needles from pet. ether–dichloromethane).  $[\alpha]_D^{25}$  –23° (c 1.0, CHCl<sub>3</sub>). IR (neat): 3434, 1708 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.37 (s, 1H, OH<sub>5</sub>), 3.17 (s, 1H, OH<sub>3</sub>), 3.31 (s, 1H, OH<sub>2</sub>), 3.48 (dd, 1H, H<sub>5a</sub>, *J*<sub>5a-5b</sub> = 10.3, *J*<sub>5a-4</sub> = 2.6), 3.65 (dd, 1H, H<sub>5b</sub>, *J*<sub>5b-5a</sub> = 10.3, *J*<sub>5b-4</sub> = 1.7), 3.67 (s, 3H, CH<sub>3</sub>), 3.78 (m, 1H, H<sub>4</sub>), 3.92 (s, 3H, CH<sub>3</sub>), 4.05 (m, 1H, H<sub>3</sub>), 4.21 (m, 1H, H<sub>2</sub>), 4.94 (d, 1H, H<sub>1</sub>, *J*<sub>1-2</sub> = 7.8), 7.29–7.38 (m, 5H, Ph), 9.96 (s, 1H, NH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 51.9, 52.4, 62.5, 70.6, 75.6, 77.6, 85.5, 121.6, 122.0, 127.5, 127.7, 128.0, 130.5, 132.3, 133.5, 160.5. Anal. Calcd for C<sub>19</sub>H<sub>21</sub>NO<sub>8</sub>: C, 58.31; H, 5.41; N, 3.58. Found: C, 58.63; H, 5.32; N, 3.39.